RecruitingPhase 4interventionalRules rewrite

Phase 4: testing First dose rimegepant, second dose placebo for Vestibular Migraine

Q: Is NCT07871097 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07871097?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07871097?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.

Official registry: https://clinicaltrials.gov/study/NCT07871097 · Wensheng Qu · enrollment listed as 80

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are First dose rimegepant, second dose placebo, or First dose placebo, second dose rimegepant. The registry lists allocation as randomized. To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.

They plan to enroll about 80 people at Wuhan. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Efficacy of Rimegepant in the Treatment of Acute Vestibular Migraine -- Multicenter, Prospective, Cross-design, Randomized, Placebo-controlled Study

Interventions: First dose rimegepant, second dose placebo, First dose placebo, second dose rimegepant

Primary outcome (registry wording): Vertigo symptom relief rate

Who it is for (from inclusion criteria)

Ages 18 Years to 60 Years
Age 18-60 years, male or female
Diagnosis of vestibular migraine according to the Bárány Society criteria
≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \>2 hours (without intervention)

Who the registry excludes

Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media)
Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks
Severe hepatic dysfunction (ALT and/or AST \>3× upper limit of normal) or renal impairment (creatinine clearance \<30 mL/min)
Severe cardiovascular or cerebrovascular disease
Alcohol abuse or substance abuse
Known pregnancy or lactation, or a positive pregnancy test prior to randomization
Contraindication or hypersensitivity to any medications used in the study

Public study contact (from the registry)

Wensheng Qu

18971622660

qws0309@163.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Tongji Hospital — Wuhan, Hubei, China (recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 3Birmingham, Alabama

Phase 3: testing Rimegepant/BHV3000 for Pediatric Migraine

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3Scottsdale, Arizona

Phase 3: testing Rimegepant (PF-07899801) for Acute Treatment of Migraine

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3New Haven, Connecticut

Phase 3: testing Eptinezumab for Chronic Migraine in Children

To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S

FAQ about this NCT record

Is NCT07871097 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07871097?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07871097?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary